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[57] ABSTRACT
Thepresent invention involves the synthesis and use of
new platinum compounds. These new platinum com-
pounds are easy to encapsulate in liposomes at high
efficiencies. They are further characterized as platinum
(II) four coordinate complex. having the formula:
Ri
R Pap~ \R2
wherein R; and R2 are carboxylato monoanionsbearing
a hydrophobic radical function or a single carboxylato
dianion bearing a hydrophobic radical function and R3
is a vicinal diaminoalkane or vicinal diaminocycloal-
kane. The complex is substantially soluble in methanol
or chloroform and substantially insoluble in water. Said
complex may be incorporated into phospholipid lipo-
somes. Such platinum complexes encapsulated in phos-
pholipid liposomesare useful for chemotherapyofplati-
num complex-sensitive tumors.
18 Claims, No Drawings
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HYDROPHOBIC CIS-PLATINUM COMPLEXES
EFFICIENTLY INCORPORATED INTO
LIPOSOMES
This patent application is a divisional of U.S. Patent
application Ser. No. 914,591, filed on Oct. 7, 1986, now
U.S. Pat. No. 5,041,581 which was a continuation-in-
part of U.S. Patent application Ser. No. 788,750,filed on
Oct. 18, 1985, now abandoned.
BACKGROUNDOF THE INVENTION
This invention relates to newly synthesized platinum
complexes with hydrophobic properties. The use of
liposomesincorporating these new and previously syn-
thesized complexes in anti-tumor chemotherapyis also
described.
Cis-platinum (CDDP)is a highly effective drug in the
treatment of several neoplastic diseases in humans (Lo-
ehrer et al (1984) Ann. Int. Med. V 100, pp 704-713).
However,its use is limited by severe systemic toxicity,
particularly nephrotoxicity and neurotoxicity (Zwelling
et a] Platinum Complexes. In: Pharmacologic principles
of cancer treatment (1982) Ed by B. A. Chabner, Saun-
ders, Philadelphia, Pa.). In an attempt to modify the
therapeutic index of CDDP,new derivatives have been
synthesized during the last decade. However,the devel-
opment of some promising analogues has been pre-
vented by their low hydrosolubility, which decreases
their potential for clinical use (Burchenal et al (1979)
Cancer Treat. Rep. V 63, pp 1493-1497).
Liposomesare lipid vesicles which may form sponta-
neously upon addition of an aqueoussolution to a dry
lipid film (Mayhewetal, In: Liposomes (1983) Ed by
Marc J. Ostro, Marcel Dekker, Inc., New York, N.Y.).
Liposomes maybe used as drug carriers of hydrophobic
or hydrophilic drugs entrapped in their hydrophobic or
hydrophilic compartments respectively. Multilamellar
liposomes are multilayer lipid vesicles (MLV) that are
particularly suited for carrying hydrophobic drugs
since their hydrophobic compartment is larger than
their hydrophilic compartment. When injected intrave-
nously (iv) in animals, (Kasi et al (1984) Int. J. Nucl.
Med. Biol. V 11 pp 35-37, Lopez-Berestein et al.
(1)(1984) Cancer Drug Deliv. V 1, pp 199-205) and
humans(Lopez-Beresteinet al (2)(1984), Cancer Res. V
44, pp 375-378), MLV concentrate in the liver, spleen
and other organsrich in reticuloendothelial (RES)cells.
Liposomes have been previously used in vitro to
deliver chemotherapeutic agents, (Mayhewetal, Lipo-
somes (1983), Ed by Ostro, Marcel Dekker, Inc., New
York, N.Y.) and immunomodulators and anti-fungal
agents in vitro (Mehta et al (1984), Immunology V 51
pp 517-527, and in vivo in animals (Lopez-Berestein et
al (4)(1984) Clin Exp Metastasis V 2 pp 127-137 and
Lopez-Berestein et al (1983), J Inf Dis V 147, pp
937-945) and in humans (Lopez-Berestein et al (1985) J.
Inf. Dis. V 151 pp 704-710).
Recent studies show that liposomes can reduce cer-
tain types of drug-related toxicities such as doxorubicin
cardiotoxicity (Forssen et al (1981) Proc. Natl. Acad.
Sci. V 78 pp 1873-1877, Olson etal (1982), Eur. J. Can-
cer Clin. Oncol. V 18 pp 167-176, Gabizon et al (1982)
Cancer Res. V 42 pp 4734-4739, Herman et al (1983)
Cancer-Res. V 43 pp 5427-5432) and CDDP nephro-
toxicity, (Freise et al (1982), Arch. Int. Pharmacodyna-
mie Therapie V 258 pp 180-192) and may increase anti-
tumoractivity as a result of a slow release mechanism
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(Mayhewet al (1978) Ann. N.Y. Acad. Sci. V 308, pp
371-386, Patel et al (1984) Int. J. Cancer V 34 pp
717-723) a higher drug uptake by tumorcells or due to
a moreselective organ distribution (Gabizonet al (1983)
Cancer Res. V 43, pp 4730-4735 and Mayhew et al
(1983), Cancer Drug Deliv. V 1 pp 43-58). In U.S. Pat.
No.4,330,534 N4-acylcytosine arabinoside incorporated
into liposomes, for example, was found to be therapeuti-
cally effective when administered to tumor-bearing
animals. In spite of these promising results, the clinical
application of antitumor agents encapsulated in lipo-
somes has been delayed, mainly due to formulation,
drug stability and large scale production problems.
CDDPhas been previously encapsulated in MLV but
with a very low encapsulation efficiency (7.4%) and
poor stability (75% at 48 hours in 0.9% NaClsolution)
(Freise et al (1982) Arch. Int. Pharmacodynamie Thera-
pie V 258 pp 180-192).
In U.S. Pat. No. 4,256,652 are described certain plati-
num compounds comprising resolved stereoisomers of
1,2 diaminocyclohexane (DACH). Theisomersutilized
were cis-DACH, trans-RR-DACH and _trans-SS-
DACH. The platinum compounds described therein
contained, in addition to a resolved DACHisomer, two
hydrophilic platinum ligands such as bromide, iodide,
nitrate, bromoacetate, sulfate or glucuronate. Theplati-
num compoundscomprising the trans-RR-DACH were
described as often more therapeutically effective than
those bearing cis-DACH.
In European Patent Application No. 83306726.7 cer-
tain platinum compounds are described which may
comprise diaminocyclohexane (non-stereochemically
resolved) and do comprise phosphatidyl groups having
fatty acid substituents. These compoundsare described
as largely insoluble in plasma and preferably employed
with lipid vesicle carriers. The platinum compound-
phospholipid vesicles were preferably prepared by a
sonic oscillation procedure which characteristically
yields unilamellar vesicles.
SUMMARYOF THE INVENTION
The present invention comprises a platinum (IT) four-
coordinate complex having the formula:
R3 Ry
Pan\R2
In this formula R; and R2 are each carboxylates bearing
a hydrophobic radical function, most preferably neode-
cyl, or, when linked together, are a dicarboxylato bear-
ing a hydrophobic radical function. The R3 and R, are
each:
H- 4—NORs
H
In this latter formula, Rs is selected from the group
consisting of hydrogen, an alky! having from 2 to 6
carbon atomssuchas isopropyl, aryl, aralkyl, alkenyl, a
cycloalkyl such as cyclohexyl, cycloalkenyl and a com-
bination thereof. Rs is preferably hydrogen, alkyl hav-
ing between 1 and 20 carbon atoms, more preferably
between 6 and 12 carbon atoms and most preferably
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between 2 and 6 carbon atoms or cycloalkyl having
between 3 and 12 carbon atoms.
Additionally R3 and R4 may be linked together in a
single function. When R3 and Ry,areso linked together,
they are preferably selected from the group consisting 5
of cycloalkyl-1,2-diamino functions having between
about 3 and 7 carbon atoms, and alkyl-1,2-diamino hav-
ing between about 2 and 12 carbon atoms, preferably
ethyl. A preferred cycloalkyl-1,2-diamino componentis
1,2-diaminocyclohexane,preferably in the trans-R,R- or 10
trans-S,S- form.
In the above-described complex the carboxylato of
Ri and R2 is preferably an alkylcarboxylato having
between about 5 and 20 carbon atoms, an arylcarbox-
ylato wherein aryl is phenyl, naphthyl, or an alkyl- 15
pheny! wherein the alkyl phenyl] has between about 12
and 16 carbon atoms.
When the complex contains Rj and R2 as a dicarbox-
ylato, the dicarboxylato is preferably an alkyldicarbox-
ylato having between about 5 and 20 carbon atoms, or
an aryldicarboxylato wherein aryl is naphthyl, phenyl,
or alkylpheny] wherein the alky! of the alkylphenyl] has
between about 6 and 12 carbon atoms.As used in the
above description the term ary] is defined further as a
function preferably having between about 6 and 14
carbon atoms. Likewise the term alkenyl is preferably a
function having between about 5 and 20 carbon atoms.
The cycloalkyl] referred to in the present descriptions
is preferably a function having between about 3 and 12
carbon atoms. The cycloalkenyl term as used aboveis
preferably a function having between about 5 and 20
carbon atoms. The term aralkyl as used aboveis a func-
tion preferably having between about 7 and 20 carbon
atoms and contains linked aryl and alkyl portions. The
aryl portion herein preferably has between about 6 and
10 carbon atoms and the alkyl portion preferably has
between about | and 10 carbon atoms. When R3 and R4
are taken together they are preferably a cycloalkyl-1,2-
diamino having between about 3 and 20 carbon atoms. 4p)
Thealky] ring of the cycloalkyl preferably has between
about 3 and 12 carbon atoms.
A further aspect of the present invention concerning
the platinum (IJ) four-coordinate complex having the
formula:
R3 Ry}NZPrt\Ry R2
concerns the case where Ry and Raz, taken together, are
a dicarboxylato, preferably a cis dicarboxylato, of the
formula:
Ri/
ooc—CHNy Re
7/O0C—CH\Rg
where Rgis alky! having between about 10 and 20 car-
bon atoms, preferably pentyl, neopentyl, decyl or 65
neodecyl and R7 and Rg are each hydrogen or an alkyl
having between about 1! and 5 carbon atoms.
Asdescribed above R3 and Rg are each:
When R3 and Rg are taken together they are selected
from the group consisting of cycloalky]-1,2-diamino
having between about 3 and 7 carbon atoms, and alkyl-
1,2-diamino having between about 2 and 12 carbon
atoms. The cycloalkyl-1,2-diamino is preferably 1,2-
diaminocyclohexane and more preferably trans-R,R-
1,2-diaminocyclohexane or trans-S,S-1,2-diaminocy-
clohexane. This complex is, as described above, substan-
tially soluble in methanol or chloroform and substan-
tially insoluble in water.
Important aspects of the present invention involve
liposomes comprising fatty substances such as phospho-
lipids, optionally cholesterol, and the four-coordinate
platinum complexes described above, as well as the
preparation and uses of these liposomes. Liposomes of
the present invention contain the platinum complex and
the phospholipid in a preferred ratio between about I to
10 and about ! to 30, a more preferred ratio being 1 to
15.
Preferred phospholipids of these liposomes include
phosphatidylglycerol, phosphatidylcholine, sphingo-
myelin, phosphatidic acid or phosphatidylserine, the
9 more preferred phospholipids being phosphatidy!l-
glycerol, phosphatidylcholine or a combination thereof.
The most preferred phosphatidylglycerol is one consist-
ing essentially of dimyristoylphosphatidylglycerol and
the most preferred phosphatidylcholine is one consist-
ing essentially of dimyristoylphosphatidylcholine.
Whenthe liposomesof the present invention comprise
dimyristoylphosphatidylglycerol and dimyristoylphos-
phatidylcholine they are preferably in a ratio between
about 1-10 and 10-1, more preferably in a ratio of about
3 to 7.
Theliposomes of the present invention may be mul-
tilamellar, unilamellar or have an undefined lamellar
construction. A pharmaceutical composition compris-
ing the liposomesof and a pharmaceutically acceptable
carrier or diluent may be used for the therapy of disease
conditions such as cancer.
A focal point of the present invention involves a
method oftreating a host animal afflicted with tumor
cells sensitive to the presence of a platinum (II) four-
coordinate complex. This method comprises adminis-
tering to the host an amountofthe platinum (II) four-
coordinate complex described above or a liposome of
the present invention comprising a phospholipid and a
tumorcell-inhibiting effective amount of said platinum
complex. The administering step is preferably paren-
teral and by intravenous, intraarterial, intramuscular,
intralymphatic, intraperitoneal, subcutaneous, intra-
pleural or intrathecal injection or by topical application
or oral dosage. Such administration is preferably re-
peated on a timed schedule, for example twice daily for
a period of two weeks. The treatment may be main-
tained until tumor regression or disappearance has been
achieved and may be used in conjunction with other
forms of tumor therapy such as surgery or chemother-
apy with different agents.
These antitumor methods mayalso be used to inhibit
the metastatic spread of tumors such as reticulosar-
coma. A preventative pretreatment with the platinum-
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(II) complexes or liposomes comprising those com-
plexes may be used to preclude metastatic spread in a
vaccination-like manner.
DETAILED DESCRIPTION OF PREFERRED
EMBODIMENTS
Platinum (II) four-coordinate complexes were pre-
pared utilizing racemic (unresolved) DACH,trans-RR-
DACHortrans-SS-DACH.It was found that platinum
complexes comprising trans-RR-DACH or trans-SS-
DACHand two hydrophobic ligands such as cyclopen-
tene-carboxylato were more efficiently incorporated
into liposomes than were the analogous complexes com-
prising racemic DACH.
Liposomes incorporating these platinum complexes
were found to be stable in an aqueous milieu, non-
nephrotoxic and active against murine leukemia L-1210.
In a general sense, the square-planar platinum (II)
four coordinate complexes of the present invention
have the formula:
R}
R Pa)“ \R2
where R and R2 are preferably carboxylato monoan-
ions bearing a hydrophobic radical function. Ry and R2
may also be a single carboxylato dianion where the
carboxylato groups are bound to an interlinking atom
which in turn is bound to a radical function. Addition-
ally, R3 is a vicinal diaminoalkane or vicinal diaminocy-
cloalkane.It is contemplated that R3 may be composed
of two independent alkylamines, cycloalkylamines or
ammonia. These components confer upon the complex
-a substantial solubility (normally greater than about 5.0
mg/ml) in methanol or chloroform at ambient tempera-
tures and a substantial insolubility (less than about 0.5
mg/ml) in aqueous solutions at ambient temperatures.
The hydrophobic radical function, that function co-
valently pendant from the carboxyl group or from an
intermediate or linking group, may be an alkyl, substi-
tuted aryl, aryl, alkenyl, cycloalkyl or cycloalkenyl
group or even combinations of these functions such as
alkylary] or arylalkenyl, to name but two of the many
possible hydrophobic combinations. The hydrophobic
radical function characteristically has between 5 and 20
carbon atoms. When this hydrophobic radical function
comprises an alkyl or alkenyl] group, this group may be
straight or branched. Polar functions such as hydroxyl
groups, for example, substituted on the hydrophobic
radicals would tend to lessen their hydrophobicity and
may render them less useful for the purposes of the
present invention.
In certain cases the R; and R2 functions may beinter-
linked, for example when two acetate or propionate
functions are bound together by a nitrogen atom. In
these cases the R; and R>functionsare a single carbox-
ylato dianion. An alkyl hydrophobic function having
between six and twenty carbon atoms,such as n-decane,
for example, may be boundto the interlinking nitrogen
and the resultant compoundutilized in the production
of the platinum (II) four coordinate complex of the
present invention.
With certain hydrophobic radical functions (cyclo-
pentene, for example) present on the carboxylato mo-
noanion it was found that efficient incorporation of PT
complexes into phospholipid liposomes was dependent
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on characteristics of the R3 function. For example,
when R3 was 1, 2 diaminocyclohexane (DACH) the
amino groups maybe in several relative stereochemical
configurations,cis, trans-RR and trans-SS (a mixture of
these being termed “racemic’’). With platinum (II) com-
plexes containing cyclopentene radical functions (R)
and R2) and various stereochemical types of DACHit
was found that the trans-RR-DACH and trans-SS-
DACH-complexes were moreefficiently incorporated
into phospholipid liposomes (vesicles being a term
equivalent to liposomes) than were the analogous race-
mic DACH complexes.
When a hydrophobicradical function was a branched
alkyl containing nine carbon atoms such as that in.
neodecanoato, (C}9H2002, empirical formula) the incor-
poration efficiency of a platinum (II) complex compris-
ing racemic DACHortrans-RR-DACH was maximal
(100%). Thus,linear or branched alkyl radical functions
having from about 6 to about 12 carbon atoms confer
properties ofefficient phospholipid liposome incorpora-
tion upon any DACH-containing Pt (II) complex.
Liposomes containing the platinum (II) complexes
described herein may be prepared from various am-
phipathic substances including natural or synthetic
phospholipids. The phospholipids usable to produce
liposomes are numerous and not exhaustively listed
herein. since they are generally well knownin theart.
These phospholipids include but are not limited to:
lecithin, phosphatidylethanolamine, lysolecithin, lyso-
phatidylethanolamine, |phosphatidylserine,  phos-
phatidylinositol, sphingomyelin, cardiolipin, phospha-
tidic acid and the cerebrosides. Most preferable phos-
pholipids for the practice of aspects of the present in-
vention include dimyristoylphosphatidylglycerol
(DMPG) and dimyristoylphosphatidylcholine
(DMPC). Cholesterol in minor proportions ranging
from less than 1% to about 50% maybe included with
phospholipids and platinum (II) complexes to produce
liposomesofthe present invention. A preferable but not
limiting combination of DMPG and DMPChas been
found to be aratioof3 to 7although ratios between 1:10
and 10:1 are contemplated as satisfactory. Ratios of
platinum (II) complex to phospholipid between about 1
to 10 and about | to 30 are contemplated as generally
satisfactory although a 1 to 15 ratio was primarily used
in studies thus far.
Either unilamellar or multilamellar or other platinum
(II) complex—containing liposomes may be used in the
practice of the present invention. Multilamellar lipo-
somes are presently preferred since the platinum (II)
complexes of the present invention are substantially
water —insoluble and they appear to be incorporated
into the phospholipid bilayers of the liposome lamellae.
Generally, the procedure for synthesis of the plati-
num II compounds of the present invention may be
described on one scale as follows: (1) about 10 mmole
vicinal diamino cycloalkane or alkane are added to 50
ml aqueoussolution of K2Pt Cl, (3.5 g) and stirred for
six to eight hours at room temperature. The yellow
solid formed comprising cis-bis-dichloro-i,2-diamine-
Pt(i]) may be removed byfiltration and washed with
fluids such as water, methanol or acetone. The solid
may then be suspended in about 20 ml H2O and an
aqueoussolution containing about 0.75 g Ag2SO4 added
thereto. After stirring for about 24 hours in the dark,
precipitated Ag Cl may be removedbyfiltration. The
sulfato-vicinal diamine-Pt may then be dissolved in
5,186,940
about 100 ml H2O and addedto about 2m molofalkali .
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earth metal salt of a carboxylato anion prepared insitu,
and stirred therewith for about 30 minutes. After re-
moval of BaSOgby filtration, the platinum II complex
of the present. invention may be obtained, for example
by crystallization or removal of the solvent by evapora-
tion.
The methods of preparation of particular platinum
(II) complexes and chemotherapeutic treatment with
particular platinum (II) complexes described in the Ex-
amples contained later herein are readily adapted to the
production and use of analogously described and
claimed complexes bysimple substitutions of appropri-
ate vicinal diamines or hydrophobic radical-containing
carboxylato monoanions.
Liposomes comprising phospholipids and platinum
complexes (Pt-liposomes) of the present invention are
useful in inhibiting both the growth and metastatic
spread of tumors.
Such Pt-liposomes may be administered parenterally,
topically or orally. Oral or parenteral dosages of these
Pt-liposomes between about 2.5 mg/kg body weight
and 25 mg/kg body weight are contemplated as ade-
quate in most conditions. The particular dosages, if a
tumor-bearing human is being treated may vary in each
case according to the condition of the patient, the type
and extent of tumor, and particular Pt-liposome toxic-
ity.
The amount of liposomal-platinum included in the
pharmaceutical composition and the dosage utilized in
the method of treatment of the invention will vary de-
pending in each case upon the conditionsofthe patients,
the nature of the tumor undergoing treatment, antitu-
mor activity of liposomal-platinum, the toxicity and
solubility characteristics thereof, etc. Liposomal-
platinum may also be administered in combination with
other antitumor agents in a combined therapeutic regi-
men.
Parenteral administration may be intraperitoneal,
subcutaneous, intrapleural, intrathecal, intraurethral,
intravenous, intraarterial, intramuscular or intralym-
phatic. Such parenteral administration preferably in-
volves Pt-liposome suspensions in pharmaceutically
acceptable solutions such as sterile isotonic aqueous
solutions. These suspensions may be obtained fully pre-
pared or may be prepared from preformed components.
As knownto those skilled in the art, Pt-liposomes may
be prepared as pellets or powders. These pellets or
powders may be mixed with pharmaceutically accept-
able solutions to form suspensions for parenteral admin-
istration.
Topical administration of Pt-liposomes may involve
pharmaceutical compositions such as suspensions,
creams or ointments which may be obtained fully pre-
pared or prepared from Pt-liposome powdersorpellets.
Such topical administration may be near to sites of can-
cerous lesions such as the epithelium or mucosa for
example.
Oral administrations of Pt-liposomes preferably in-
volve encapsulation of Pt-liposome powder orpellets
whereby the Pt-liposomes are protected from. much
gastric and intestinal digestive activity before release
from the encapsulation.
Whendesired, Pt-liposomes maybe prepared to con-
tain, for example, other therapeutic agents for treatment
of tumors or anti-oxidants to aid in liposomestabiliza-
tion.
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Use of the complexesofthe present invention, partic-
ularly as a componentof liposomes, focuses upon the
inhibition of tumor growth and prevention of the meta-
static spread of tumors. For example, first a host is
identified as bearing a tumor type known to generally
contain cells whose growth is often inhibited by plati-
num (II) complexes. Tumor growth in the host may be
inhibited by administering to the host the PT-containing
liposomesof the present invention.
Similarly, the metastatic spread of tumors in a host
may be inhibited. A host bearing metastatic or poten-
tially metastatic tumors of a type noted often to be
sensitive to platinum (II) complexes, would first be
identified. The administration of the PT-containing
liposomes of the present invention to that host would
serve to inhibit metastatic spread.
The following examples are presented to furtherillus-
trate preferred embodiments of the present invention;
they are not intendedto limit the invention unless other-
wise so stated in the accompanying claims.
EXAMPLE1
Materials and Analyses
K2PtCl4 was purchased from AESAR (Johnson Mat-
they, Inc. Seabrook, N.H.). Cyclopentenecarboxylic
acid was purchased from Pfaltz and Bauer, Inc., Stam-
ford, Conn.; 1,2-diaminocyclohexane (DACH) from
Aldrich Chemical Co., Milwaukee, Wis., trans-RR-
DACHand trans-SS-DACH from Mortol Thiokol,
Inc., Danvers, Mo., and neodecanoic acid from Exxon
Chemical Co., Houston, Tex. Elemental analyses on the
platinum complexes were performed by Integral Micro-
analytical Laboratories, Inc., Raleigh, N.C. and by
Robertson Laboratory, Inc., Florham Park, N.J. Infra-
red spectra of the complexes (as KBrpellets) were mea-
sured in the range of 600-4,000 cm! using a Nicolet
6000 Fourier transform infrared spectrophotometer.
Chromatographically pure (thin-layer chromatogra-
phy) dimyristoylphosphatidylcholine (DMPC) and
dimyristoylphosphatidylglycerol] (DMPG) used in this
study were obtained from Avanti Polar Lipids (Bir-
mingham,Ala.). Cholesterol was purchased from Sigma
Chemical Co. (St. Louis, Mo.).
EXAMPLE2
Synthesis of
cis-bis-cyclopentenecarboxylato-1,2-DACH-platinum
(1)
Cis-bis-cyclopentenecarboxylato-1,2-DACH-
platinum (I) was onecis-platinum (CDDP) hydropho-
bic analogue used as a prototype to develop liposomal-
platinum (L-PT) preparations. The general structure of
this particular complex was as follows:
NH
pa coc-{)
NH2 2
This prototype was synthesized using a multi-step
procedureas described for racemic DACH (Khokharet
al. Inorg. Chem. Acta. Bioinorganic Section, V 108, p
63 (1985) follows: 0.96 g of DACH were added to a
filtered aqueous solution of K2PtCl, (3.5 g in 50 ml
H20)and the mixture wasstirred for six to eight hours
at room temperature. The yellow solid containing cis-
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bis-dichloro-DACH-Pt (II) was removed by filtration
and washed with H20, methanol, and finally acetone.
After the final product was dried under vacuum,the
yield was calculated to be 56%. Subsequently, 1.0 g of
cis-bis-dichloro-DACHPt (II) was suspended in 20 ml
H20 and an aqueous solution of Ag2SOg (0.75 g in 150
ml H2O) was added to obtain water soluble sulfato-
DACH-Pt H20. The reaction mixture wasstirred in the
dark for 24 hours and the precipitated AgCl wasre-
movedbyfiltration. The yeliow solution was evapo-
rated to dryness at 45°-50° C. under reduced pressure
and the yellow roduct was further dried over P2Os in
vacuum. The yield of sulfato-DACH-Pt (11) H2O was
90%. Finally, 0.423 g (1 mmol)ofsulfato-DACH-Pt(II)
was dissolved in 100 ml of H2O, and the barium cy-
clopentenecarboxylato was preparedin situ by the addi-
tion of 0.3 g of Ba(OH)2 to 0.226 g (2 mmol) of cy-
clopentenecarboxylic acid in HzO. These components
were mixed and the reaction mixture wasstirred for 30
minutes at room temperature. The BaSO, precipitate
was filtered off, and the yellow filtrate was evaporated
to dryness at 45° C. under reduced pressure using a
rotary evaporator. A yellow solid was obtained, which
was purified from methanol. The product wasfinally
dried under vacuum. Yield was 70%. Analysis: C
40.26%, H 5.65% and N 5.05% CisH30N2O4Pt (PT)
(theoretically C 40.67%, H 5.65% and N 5.27%. The
infrared spectrum for the complex (as KBr pellet)
/C=0 1632 cm—! and /C-0 1398 cm—!.
Cis-bis-cyclopentenecarboxylato-1,2-DACH-Pt (II)
is highly soluble in methanol and chloroform and only
slightly soluble in water (less than 0.5 mg/ml). The
above-described synthetic procedure was carried out
with both trans-RR-DACH and trans SS-DACH to
produce the trans-RR and trans-SS isomersofcis-bis-
cyclopentenecarboxylato-1,2-DACH-Pt (II). The anal-
ysis of cis-bis-cyclopentenecarboxylato-1,2-trans-RR-
DACH-Pt (ID-3H20 was: C-37.36%, H-5.50%, N-
_ 5.12% (theoretically C-37.93%, H-5.82%, N-4.80%).
EXAMPLE3
Synthesis of Cis-Bis-Neodecanoato-DACH-Platinum
(I)
Sulfato-racemic-DACH-platinum (II) (0.423 g), pre-
pared as described in Example 2, was dissolved in 10 ml
water. A potassium salt of neodecanoic acid (0.420 g)
was added to this solution and the reaction mixture
stirred for 30 minutes at room temperature. A gummy
mass was obtained which was extracted in chloroform
and the chloroform extract was dried over anhydrous
MgSO4. The MgSOxwasseparated byfiltration and the
filtrate evaporated to dryness. An off-white solid prod-
uct was obtained which was dried in vacuo and over
P20s. This final product was stored at 0° C.
The elemental analysis of the final product was: C-
48.30%; H-8.10% and N-3.92%. The calculated ele-
mental values for a compoundofthe empirical formula;
Cr26Hs52N204Pt. is: C-47.93%; H-8.00% and N-4.30%.
The structural formula of the cis-bis-neodecanoato-
DACH-platinum II was as follows:
NH) *
Pt oocme—R
NH? R”
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where R,R',R” can be: CH3, C2Hs or C3H7 to give a
carboxylato radical function C19H1902 (MW =172) as
empirical formula.
Cis,bis-neodecanoato-DACH-platinum (II) was
highly soluble in methanol and chloroform and insolu-
ble in water.
The above described procedure wascarried out with
trans-RR-DACH to produce the trans-RR isomer of
cis-bis-neodecanoato-DACH-Platinum (II). The analy-
sis of cis-bis-neodecanoato-RR-DACH-Platinum (ID
was: C-47.75%, H-8.16%, N-3.98% (theoretically C-
47.93%, H-8.00%, N-4.30%).
EXAMPLE4
Synthesis of
Cis-Bis-n-Decyliminodiacetato-DACH-Platinum (II)
Sulfato-DACH-platinum (IT) H2O (0.423 g), prepared
as described in Example 2, was dissolved in 10 mi of
H20.
The sodium salt of n-decyliminodiacetic acid was
prepared in situ by the addition of NaOH (0.08 g) to
N-decyliminodiacetic acid (0.273 g) in 50 ml of water.
This aqueoussolution of sodium N-decyliminodiacetato
was added to the sulfato-DACH-platinum solution and
stirred for 30 minutes at room temperature. Theresult-
ing solution was evaporated to dryness on a rotary
evaporator at 40° C. under reduced pressure. The yel-
low solid thus obtained was dissolved in methy] alcohol
and filtered through Celite. The yellow filtrate was
evaporated to dryness in a rotary evaporator under
reduced pressure A yellow crystalline product was
obtained, which was further purified from 1-propanol,
yield 80%.
An elemental analysis of the product showed: C-
39.28; H-7.12% and N-6.68%. The theoretical composi-
tion for a compound of the empirical formula,
C29H39N304Pt.2H20, was: C-38.95%; H-7.02% and
N-6.81%. The infrared spectrum for the complex (as
KBrpellet)/ C=0 1580cm—! and / C-0 1410cm—!.
The structural formula of the  cis-bis-n-
decyliminodiaceto-DACH-platinum (II) is shown as
follows:
or O0c—CHa
ooc—cn,”
where R=n-decyl or a longer straight or branched
chain alkyl radical.
Cis-bis-n-decyliminodiacetato-DACH-Platinum ()
is highly soluble in methanol and chloroform and insol-
uble in water. The above described synthetic procedure
wascarried out with trans-RR-DACH to produce the
trans-RR isomer of  cis-bis-n-decyliminodiacetato-
DACH-Pt (ID. The analysis of  cis-bis-n-
decyliminodiacetato-trans-RR-DACH-Pt (II) was: C-
38.60%, H-6.87%, N-6.82% (theoretically C-38.95%,
H-7.02%; N-6.819%).
The above described compound represents a struc-
ture where R; and R>ofthe earlier described general
structure are one and the same and the carboxylato
monoanions are bound togetherbya linking atom bear-
ing an alkyl hydrophobic radical to form, in fact, a
carboxylato dianion.
—R
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EXAMPLE5
Platinum-Containing Liposomes (L-PT)
Multilamellar lipid vesicles (MLV)or liposomes con-
taining incorporated platinum complexes (PT) of the
above descriptions were prepared as previously de-
scribed for other compounds (Lopez-Berestein et al
(4)(1984) Clin. Exp. Metastasis V 2 pp 127-137 and
Lopez-Berestein et al (1983) J Inf Dis V 147 pp
937-945). In brief, chloroform solutionsoflipids (at the
desired molar ratio) and PT were mixed at a lipid-PT
ratio of 15:1 and the chloroform was evaporated in a
rotary evaporator (Buchi, Brinkmann Instruments,
Westbury, N.Y.). The driedlipid film obtained, contain-
ing PT, was then dispersed with an aqueous solution
(0.9% NaCl in water) by vigorous handshaking. The
suspension was subsequently centrifuged at 30,000xg
for 45 minutes, the supernatant was discarded, and the
pellet containing PT was resuspended in 0.9% NaCl
solution.
MLVor liposomes containing platinum complexes
may also be prepared from a lyophilized powder con-
taining lipid and platinum compound. Thelipid and
platinum compoundare dissolved in the hydrophobic
solvent tertiary butanol (M.P. 26° C.) at the ratios de-
scribed above. The solution is freeze-dried and a white
powder obtained. MLV containing the platinum com-
pound are formed upon the addition of 0.9% NaCL
solution in water to the yophilized powder with mild
shaking by hand.
EXAMPLE6
Calculation of Encapsulation Efficiency (EE) and
Stability
Elemental platinum (Pt) was determined in the lipo-
some suspension and the pellet by x-ray fluorescence as
previously reported (Seifert et al (1979) Proc. Amer.
Ass’n. Cancer Res. V 20 p. 168) in the Department of
Analytical Chemistry, The University of Texas Medical
School at Houston, Tex. The amount of platinum com-
plex (PT) was determined in the supernatantbyultravi-
olet (UV) spectrophotometry using.a wavelength of 224
nm. The EE wasinitially calculated with the two fol-
lowing formulas:
1, EE=Pt in pellet/total Pt in the initial liposome
suspension
2. EE=Total Pt initially added—Pt in supernatant-
/total Pt initially added’
Since the results obtained by these two methods were
highly comparable and the second methodonly requires
PT determination by UV spectrophotometry, most EE
determinations were calculated with the second
method. _
The stability of the different liposome-PT (L-PT)
preparations in 0.9% NaCl solution at 4° C., and 50%
human (AB)serum in 0.9% NaClsolution at 37° C. was
determined using the following formula:
%_EE at x hoursStability at x hours = % EE at 0 hours Xx 100
The EE values used in the stability determinations
were obtained by measuring PT in the supernatants by
UV spectrophotometry (0.9% NaClsolution) or x-ray
fluorescence (50% human AB serum). Thestability in
0.9% NaCl solution was determined up to 14 days after
the initial preparation. In addition, the L-PT prepara-
tions were observed microscopically on day 14 to check
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the morphology of the vesicles. The stability in 50%
human AB serum wasdetermined up to 18 hoursafter
incubation.
Different cis-platinum analogues were encapsulated
in multilamellar vesicles composed of DMPC:DMPG
7:3. The encapsulation efficiency for Pt-cyclopen-
tenecarboxylato racemic-DACH was 66%. The encap-
sulation efficiency wassignificantly increased when the
pure trans RR DACHortrans-SS-DACHisomers were
used (88% and 90%, respectively). The encapsulation
efficiency for Pt-neodecanoato-racemic-DACH, Pt-
neodecanoato trans-RR-DACH, Pt-n-
decyliminodiacetato racemic DACH complexes are
presented in Table 1, shown below.
TABLE 1
ENCAPSULATION EFFICIENCY OF
L-PT USING DIFFERENT ANALOGUES
% Encapsulation.
 
Piatinum Analogue Efficiency!
Pt-cyclopentenecarboxylato 66
racemic-DACH mixture
Pt-cyclopentenecarboxylato 88
trans-RR-DACH
Pt-cyclopentenecarboxylato 90
trans-SS-DACH
Pt-neodecanoato-racemic 99
DACH-mixture
Pt-neodecanoato-trans-RR-DACH 99
Pt-N-decyliminodiaceto-racemic- 100
DACH mixture
Pt-N-decyliminodiacetato-trans-RR-DACH 98
 
'Mean ofat least three experiments. Liposome composition: DMPC:DMPG7:3
Analogous experiments (not shown) with DMPC
alone, DMPG alone, cholesterol alone, DMPC and
DPMG combined in other concentrations, with or
without cholesterol showed no better encapsulation
efficiency and, most frequently, a significantly de-
creased EE.
EXAMPLE7
Stability of L-PT in Aqueous Milieu
Preparations were suspendedin 0.9% saline and incu-
bated at 4° C. for 14 days. The liposome compositions
were observed by light microscopy and the amountof
free PT in the saline determined. Liposomescontaining
- PT and composed of DMPGasthe only phospholipid
50
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showed significant microscopically determined loss of
structure. Free PT was determined and stability was
calculated as the percentage PT remaining in the lipo-
somes. The results of these measurements are presented
in Table 2 below.
 
TABLE 2
STABILITY OF L-PT IN SALINE L-PT AT 14 DAYS!
Platinum Analog Stability %
Pt-cyclopentenecarboxylato-racemic-DACH 89
Pt-cyclopentenecarboxylato-trans-RR-DACH 94
Pt-cyclopentenecarboxylato-trans-SS-DACH _
Pt-neodecanoato-racemic-DACH 100
Pt-neodecanoato-trans-RR-DACH 99
Pt-iminodiacetato-racemic-DACH 100
Pt-iminodiacetato-trans-RR-DACH 100
 
‘Liposome composition: DMPC:DMPG 7:3
As may be seen in the above data, both the Pt cy-
clopentenecarboxylato trans-RR-DACH and the Pt-
neodecanoato-racemic-DACH exhibit greater stability
than the Pt cyclopentenecarboxylato-racemic-DACH.
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EXAMPLE8
Toxicity Studies of L-PT
(Cyclopentenecarboxylato-racemic-DACH). . . . 3Toxicology studies were carried out in 6-8 weeks old
CD-1 Swiss mice weighing 22-25 gm and purchased
from The University of Texas Science Park (Bastrop,
Tex.). Free PT in suspension in hydroxypropyicel-
lulose, DMPG, DMPG-PT, DMPC:DMPG 7:3 and
DMPC:DMPG7:3-PT were administered intraperito-
neally (ip) in volumes ranging between 0.1 and 0.3 mi.
DMPC:DMPG 7:3-PT. was also administered intrave-
nously (iv) in one single injection or in 3 daily injec-
tions. Theclinical behavior and the survival times were
monitored on a daily basis. The LDi9, LDso and LDoo
were calculated considering the deaths occurring up to
14 days after injection.
PT in suspension in hydroxypropylcellulose, DMPG-
PT and DMPC:DMPG7:3-PT had a similar LDs59 dose
level when given in a single intraperitoneal (ip) injec-
tion (91 mg/kg, 86 mg/kg and 75 mg/kg respectively)
(Table 3). The amount of PT that would be encapsu-
lated at the LDso dose level of empty liposomes com-
posed of DMPG and DMPC:DMPG7:3 was higher
(183 mg/kg and >304 mg/kg respectively). The LDs0
dose for DMPC:DMPG7:3-PT injected iv was similar
for the two schedules used: single injection and daily x
3 injections (82 mg/kg vs 96 mg/kg). Most deaths in
both the ip and iv toxicity studies occurred between day
5 and 10 after injection. The results of these studies are
presented in Table 3.
TABLE3
TOXICITY OF DIFFERENT L-PT PREPARATIONS
(CYCLOPENTENECARBOXYLATO-RACEMIC-DACH)
ADMINISTERED IP AND IV
 
L-PT Route of LD;}o LDs0 LDoo
Preparation Administration mg/kg mg/kg mg/kg
Free PT ip x1 61 91 125
DMPG-PT ip x 1 36 86 133
DMPC:DMPG 7:3-PT ip x 1 54 75 94
iv x 1 _ 82 100
ivqd x 3 63 86 107
DMPG* ip x 1 158 183 228
DMPC:DMPG7:3" ip x 1 >304 =>304 >304
 
*Results expressed in mg/kg of PT that would be encapsulated at the LDio, LDsg
and LDog dose levels of empty liposomes.
EXAMPLE9
NEPHROTOXICITY
Blood urea nitrogen (BUN) was determined in sam-
ples obtained from the retroorbital plexus of CD; Swiss
mice weighing 22-25 gm 96 hours after the ip injection
(single dose) of CDDP, PT cyclopentenecarboxylato
racemic DACHin hydroxypropylcellulose, DMPG-PT
or DMPC:DMPG7:3-PT at doses corresponding to the
previously determined LDso. All L-PT preparations
tested for toxicity were prepared under sterile condi-
tions on the same day of the experiments. There were
no significant BUN elevations after the ip administra-
tion of the LDso dose of PT in suspension in hydroxy-
propylceilulose, DMPG-PT and DMPC:DMPG 7:3-
PT (BUNat 96 hours 34.49.6 mg %, 30.044.6 mg %
and 32.0+2.3 mg % respectively). The results are
shownbelow in Table 4.
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TABLE 4
ACUTE NEPHROTOXICITY OF CDDP, FREE
PT (CYCLOPENTENECARBOXYLATO-RACEMIC-DACH)
AND L-PT AT THE LDsp DOSE IN CD) MICE
 
 
LDs59 Dose
ip Single Injection BUNat 96 hours!
Preparation (mg/kg) (mg %)
CDDP 17 78.3 + 8.0Free PT 91 34.4 + 9.6
DMPG-PT 86 30.0 + 4.6
DMPC:DMPG 7:3 75 32.0 + 2.3
'Normal = 27.2 + mg %
EXAMPLE10
In Vitro Antitumor Activity of
Cyclopentenecarboxylato-Racemic-DACH-Pt AgainstL1210 Cells
11210 leukemic cells were grown in a suspension
culture in McCoy’s 5A medium (Gibco Laboratories,
Grand Island, N.Y.) supplemented with 10% horse
serum, glutamine, streptomycin and penicillin at 37° C.,
95% relative humidity in a 5% COz atmosphere. Four
ml ofcell suspension were added to culture tubes and
the appropriate concentration of free PT or L-PT was
added (from 0.01 micro g/ml to 10 micro g/mlfinal
concentration). After 96 hours,the cell concentration of
control and experimental cultures were calculated. with
a Coulter Counter (Coulter Electronics, Hialeah, Fla.)
and the percent inhibition calculated. The followingpreparations were tested: free PT, DMPG,
DMPC:DMPG 7:3, DMPG-PT and DMPC:DMPG
7:3-PT. Results were expressed as the dose achieving a
50% growth inhibition (IDso). Results for empty lipo-
somes were expressed as the amount of PT that would
have been encapsulated at the IDs concentration.
The IDso for free cyclopentenecarboxylato-racemic
DACHwas1.3 micro g/ml (Table 5). Of the two L-PT
preparations tested, DMPG-PT wasslightly more ac-
tive than DMPC:DMPG 7:3-PT (mean IDsof three
experiments; 0.7 and 1.6 micro g/ml respectively).
Empty liposomes composed of DMPG had an IDs0 of
3.7 micro g/ml while the IDso for empty liposomes
composed of DMPC:DMPG7:3 was>10 micro g/ml
(Table 5).
TABLE 5
IN VITRO ANTITUMORACTIVITY AGAINST L1210
CELLS OF FREE PT, L-PT AND EMPTY LIPOSOMES
(where PT is cyclop arboxylato-racemic-DACH-PT)
 
 
IDsp (micro g/ml)!
Preparation Exp. 1 Exp.2 Exp. 3 Mean
Free PT 1.3 _ _ —
DMPG-PT 0.7 1.0 14 0.7DMPG? 3.0 3.0 5.0 3.7
DMPC:DMPG 7:3-PT 1.9 2.0 0.9 1.6DMPC:DMPG7:32 > 10.0 _ — _
CDDP IDso = 0.1 micro g/ml
21Dsp expressed as micro g/m! of PT that would be encapsulated at the IDso
concentration of empty liposomes.
EXAMPLE11
In Vivo Antitumor Activity of L-PT Against L1210
Mouse Leukemia where PT is
cyclopentenecarboxylato-racemic-DACH
The in vivo antitumor activity of CDDP, PT in hy-
droxypropylcellulose, DMPG, DMPG-PT,
DMPC:DMPG 7:3, and DMPC:DMPG 7:3-PT was
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tested in an L1210-BDF| mouse model (25). BDF; mice
were purchased from Charles River (Wilmington,
Mass.). Groups of 6-8 mice weighing 18-22 gm were
inoculated ip with 1x 106L1210 leukemia cells on day
0. L1210 cells were kept in DBA2 mice were weekly
passages between the different experiments. All L-PT
preparations were injected ip in volumesof 0.1 to 0.3 ml -
24 hours after tumor inoculation. Two different sched-
ules of administration were used: a single injection on
16
CDDP, DMPG-PT and DMPC:DMPG7:3-PT (Table
6).
In the experiment using a multiple dose schedule, the
highest % T/C obtained was 253 for CDDP 7.5
mg/kg X3, 284 for free PT 12.5 mg/kg x 3, 179 for
DMPG-PT 6.25 mg/kg X3 and 403 for DMPC:DMPG
7:3-PT 12.5 mg/kg x3. Long-term survivors (1 of 6
mice) were only observed in the group treated with
DMPC:DMPG7:3-PT (Table 7).
TABLE6
 
IN VIVO ANTITUMOR ACTIVITY AGAINST MOUSE L1210 LEUKEMIA
OF CDDP, FREE PT AND L-PT ADMINISTEREDIP (DAY 1)
where PT is cyclopentenecarboxylato-racemic-DACH
% T/C
Group . (Number of Survivors on Day 30)
Number Preparation* Exp. 1! Exp. 22 Exp. 33
1 CDDP 10 mg/kg 167 - 189 (1/6)
2 Free PT 25 mg/kg — - 1683 12.5 mg/kg 173 136 179
4 DMPG-PT 25 mg/kg 100 _ =-5 12.5 mg/kg 160 209 (2/6) 158
6 6.25 mg/kg — _ 1587 3.12 mg/kg — _ 163 (2/6)
8 DMPC:DMPG7:3-PT 25 mg/kg 213 200 (1/6) 232 (1/6)
9 12.5 mg/kg 167 (1/6) _ 189 (1/6)
10 6.25 mg/kg — _ 200
 
Imedian survival of control = 7.5 days
2median survival of control = 11 days
3median survival of control = 9 days
4All preparations were injected ip in 0.1-0.3 m! 24 hours after the ip inoculation of 1 x 10° L1210 cells.
day 1 or an injection on days 1, 5 and 9 (multiple). The
doses of CDDPused were the onesthat had resulted in
a maximum antitumoractivity in previous experiments.
The doses of PT, DMPG-PT and DMPC:DMPG7:3-
PT used ranged from 3.125 mg/kg to 50 mg/kg (ap-
proximate LDj9). Clinical behavior and survival times
were monitored until all animals had died. Results were
expressed as % T/C (median survival] time of treated
mice/median survival time of control mice x 100) and
numberof long-term survivors. Mice living more than
30 days and more than 60 days were considered to be
long-term survivors for the single and multiple injection
schedule respectively All L-PT preparations tested for
antitumor activity were prepared understerile condi-
tions on the same day of the experiment. In the first set
of experiments, the effect of a single ip dose of CDDP,
free PT, DMPG-PT and DMPC:DMPG7:3-PT in the
treatment of L1210 leukemia was tested. Mice treated
with free PT at doses of 12.5 mg/kg and 25 mg/kg had
a % T/C comparable to those treated with 10 mg/kg of
CDDP(162 vs 178, means of three experiments) (Table
6). DMPG-PTat doses of 12.5 mg/kg, 6.25 mg/kg and
3.125 mg/kg had an antitumor activity comparable to
free PT and CDDP (mean % T/C=175 for 12.5
mg/kg; 158 for 6.25 mg/kg; and 163 for 3.125 mg/kg)
(Table 6). Doses of DMPG-PT of 25 mg/kg or more
were toxic for L1210 leukemia-bearing BDF). mice.
Mice treated with DMPC:DMPG7:3-PT at doses of 25
mg/kg, 12.5 mg/kg and 6.25 mg/kg had a similar or
slightly higher % T/C than those obtained with
CDDP, free PT and DMPG-PT (mean: % T/C=215
for 25 mg/kg; 178 for 12.5 mg/kg; and 200 for 6.25
mg/kg) (Table 6). DMPC:DMPG 7:3-PT at a dose of
50 mg/kg was toxic for L1210 leukemia-bearing BDFi
mice. Empty liposomes composed of DMPG and
DMPC:DMPG 7:3, at doses equivalent to the optimal
ones of loaded vesicles (L-PT) did not shown antitumor
activity (% T/C=105 for DMPG and 93 for
DMPC:DMPG7:3). Long-term survivors (one or two
mice of six) were seen in the groups treated with
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TABLE 7
IN VIVO ANTITUMOR ACTIVITY AGAINST MOUSE
L1210 LEUKEMIA OF CDDP, FREE PT AND L-PT
ADMINISTEREDIP (DAYS1, 5 and 9) WHERE
PT IS CYCLOPENTENECARBOXYLATO-RACEMIC-DACH
 
% T/C (Numberof
Group Survivors
Number Preparation! Dose on Day 60)
1 CDDP 7.5 mg/kg X 3 253
2 Free PT 25 mg/kg X 3 158
3 12.5 mg/kg X 3 284
4 6.25 mg/kg X 3 168
5 DMPG-PT 12.5 mg/kg x 3 105
6 6.25 mg/kg X 3 179
7 3.12 mg/kg X 3 168
8 1.56 mg/kg xX 3 115
9 DMPC:DMPG7:3-PT 12.5 mg/kg x 3 403 (1/6)
10 6.25 mg/kg x 3 253
11 3.125 mg/kg X 3 210 (1/6)
 
‘ANpreparations were injected ip in volumes of 0.1 to 0.3 ml 24 hours, 5 days and
9 days after tumor inoculation
EXAMPLE12
In Vivo Antitumor Activity of Different L-PT Analogs
Against L-1210 Leukemia
The antitumoractivity against L-1210 murine leuke-
mia of the different L-PT analogs was assessed in an
L-1210-BDF, mouse model (tumor inoculation day 0,
treatment day 1, ip) as described earlier herein. Com-
pared with CDDP (% T/C=175), the L-PT analogues
showed equivalent or slightly higher anti-tumor activ-
ity, with the exceptions of L-PT (cyclopentenecarbox-
ylato trans-SS-DACH=155 and N-decyliminodiaceto
racemic-DACH=150 and N-decyliminodiacetato
trans-RR-DACH=162). These results are shown in
Table 8.
17
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cells (inoculation day 0) compared with cis-platinum
 
ANTITUMOR EFFECT AGAINST L1210
LEUKEMIA? OF CIS-PLATINUM AND
DIFFERENT LIPOSOMAL-PLATINUM ANALOGUES!
(10 mg/kg on day -1) and untreated animals (mean num-
ber of liver metastases+ SD=52+20 for L-PT, 256454
for cis-platinum. and 226+21 for control) (Table 11).
 
 
 
. Dose* TABLE 9Platinum Analog mg/kg % T/C?- Treatment of Liver Metastases of M5076 ReticulosarcomaPT-cyclopentenecarboxylato-racemic-DACH 25 213 with L-PT-NEODECANOATO-RACEMIC-DACH
PT-cyclopentenecarboxylato-trans-RR-DACH 25 187 No. Liver
PT-cyclopentenecarboxylato-trans-SS-DACH 25 155 . .
PT-neodecanoato-racemic-DACH 50 187 10 pay 30 t Dose Schedule Metastases0”PT-neodecanoato-trans-RR-DACH 25 175 rearmen mek ay_ mean =
PT-N-decyliminodiacetato-racemic-DACH 25 150 Cis-platinum 75 8, 12, 16 114 + 38
PT-N-decyliminodiacetato-trans-RR-DACH 25 162 L-PT-NEODECANOATO- 25 8, 12, 16 39 + 21
Cis-platinum (CDDP)> 10 175 RACEMIC-DACH
1Liposome composition: DMPC:DMPG 7:3 *Groups of 10 C57BL/6 mice were inoculated on day 0 with 10° M5076 cells
2 Wedian survival of treated mice 15 intravenously. Animals were treated.on days 8, 12, and 16 with cis-platinum or
Median survival of control mice x 100 L-PT-NEODECANOATO-RACEMIC-DACH.The median survival of untreated
31 x 1011210 cells inoculated ip on day 0. animals was 19 days. Treated animals were sacrificed on day 30,thelivers dissected,
“Treatment: ip on day 1 placed in Bouin's fixative, and the numberofliver-tumor colonies counted.
3Dissolved in saline, 1 mg/ml
TABLE10
Treatment of Liver Metastases of M5076 Reticulosarcoma
with L-PT-NEODECANOATO-RACEMIC-DACH
Day 45 Dose Schedule No. Liver Metastases on
Treatment mg/kg day mean + SD
Cis-platinum 7.5 24,812 0,0, 175, >200, >200, >200
L-PT-NEODECANOATO- 25 4, 8, 12 0, 0, 0, 0, 0, 1
RACEMIC-DACH
"Groups of 6 C57BL/6 mice were inoculated on day 0 with 104 M5076 cells intravenously. Animals
were treated on days 4, 8, and 12 with cis-platinum or L-PT-NEODECANOATO-RACEMIC-
DACH.The median survival of untreated animals was 30 days. Treated animals were sacrificed on
day 45, the livers dissected. placed in Bouin's fixative, and the numberof liver-tumor colonies
counted. Two ofthe animals treated with cis-platinum died before day 45 versus nonein the group
treated with L-PT.
EXAMPLE13
In Vivo Antitumor Activity of
L-PT-NEODECANOATO-RACEMIC-DACH
Against Liver Metastases of Mouse M5076
Reticulosarcoma
The potential antitumoreffect of L-PT against liver
metastases was tested using L-PT-
NEODECANOATO-RACEMIC-DACHprepared as
described in Example 6 and the mouse M5076reticulo-
sarcoma, which is a tumor that metastasizes exclusively
to the liver.
L-PT-NEODECANOATO-RACEMIC-DACH
was more active than cis-platinum in the treatment of
established liver metastases of M5076 using two differ-
ent tumor inocula and schedules of administration
(Table 9 and 10). L-PT-NEODECANOATO-
RACEMIC-DACH (25 mg/kg on days, 8, 12, 16) re-
sulted in a more than two fold reduction in the number
of liver metastases compared with cis-platinum (7.5
mg/kg on days, 8, 12, 16) on day 30 after the intrave-
nous inoculation of 105 M5076 cells (mean numberof
liver metastases+SD=39+21 for L-PT vs 114238 for
cis-platinum (Table 9). L-PT-NEODECANOATO-
RACEMIC-DACH (25 mg/kg on days 4, 8, 12) re-
sulted in the complete inhibition of liver metastases of
M5076 on day 45 after the inoculation of 104 M5076
cells, while 4/6 animals treated with cis-platinum (7.5
mg/kg on days 4,8, 12) had 175 or more liver metasta-
ses (Table 10).
L-PT-NEODECANOATO-RACEMIC-DACH
was effective in the prophylaxis of liver metastases of
M5076 reticulosarcoma. L-PT-NEODECANOATO-
RACEMIC-DACH(37.5 mg/kg on day -1) resulted in
a five-fold decrease in the numberof liver metastases on
day 21 after the intravenous inoculation of 10+ M5076
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TABLE11
Prophylaxis of Liver Metastases of M5076 Reticulosarcoma
with L-PT-NEODECANOATO-RACEMIC-DACH*
 
No.Liver
Day 21 Dose Schedule Metastases on
Treatment mg/kg day mean + SD
None _ _ 226 + 21
Cis-platinum 10 -1 256 + 54
L-PT-NEODECANOATO- 37.5 -1 52 + 20
RACEMIC-DACH
*Groups of 6 CS7BL/6 mice were treated on day —1 with cis-platinum or L-PT
Neodecanoato-Racemic-DACH.Animals were inoculated on day 0 with 10 M5076
cells intravenously. The median survival of untreated animals was 21 days. Treated
animals were sacrificed on day 21, the livers dissected, placed in Bouin's fixative,
and the number of tumor colonies counted.
EXAMPLE14
Preparation of
cis-bis-neodecanoato-cis-diamine-platinum (II).
Cis-diamine-diiodo-platinum (IT) (NH3)2 Pt-I2 was
first prepared by the following method:
K> PtCly (5 g) was dissolved in water (20 ml). An
aqueous solution of KI (3 g) was added and a dark
brown solution was obtained. Aqueous concentrated
ammonia (2 ml) was added to the mixture which was
stirred for 2~3 hr. at room temperature. The mixture
wasfiltered and the solid was washed with an excess of
water, ethanol and ether. The product was dried over
P20; under vacuum. Yield 4.5 g (77%).
The compoundaccording to the invention was then
prepared as follows:
(NH3)2-Pt-I2 (1.0 g) was suspended in water (50 ml),
and aqueous solutions of AgNO3 (0.68 g 20 mi H20)
was added thereto. The reaction mixture was stirred
overnight at room temperature in the dark. The Agl
precipitate wasfiltered andfiltrate was concentrated by
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rotary evaporation. To the concentrated solution a solu-
tion of sodium neodecanoato preparedin situ, (neodeca-
noic acid 0.688 g in 20 ml methanol and 1N NaOH,4
mil) was added. The reaction mixture wasstirred over-
night at room temperature. The yellow reaction mix-
ture was evaporated to dryness at 40° C. under reduced
pressure using a rotary evaporator. A gummy product
was obtained which was extracted in chloroform and
the chloroform extract was dried over anhydrous
MgSO. MgSOszwas separated byfiltration andfiltrate
was evaporated to dryness under reduced pressure
using a rotary evaporator. A cream-color solid was
obtained which was dried over P20in vacuo. Thefinal
product was stored at 0° C.
The elemental analysis of the final product was
C41.58, H8.03; N 4.45%. The calculated values for
Cr0H44N24Pt. is C42.00; H7.7, N4.90%.
The structural formula of the cis-bis-neodecanoato-
bis-diamine-platinum (IJ), is as follows:
[H3N}2.—Pt—[OOC—CR’RR"}
where R, R’, R” can be CH3, C2 Hs or C3H7 to give a
carboxylato radical function with Cio9H}9Q2
(MW=171) as empirical formula.
Cis-bis-neodecanoato-bis-diamine-platinum (II) is
highly soluble in chloroform, methanol and other com-
mon organic solvents, but insoluble in water.
EXAMPLE15
Preparation of cis-bis-neodecanoato-bis
cyclohexylamine-platinum (II) dihydrate
The method of Example 14 was followed, using the
cyclohexylamine ligand in place of ammonia. The com-
plex is highly soluble in chloroform, methanol and other
organic solvents, but insoluble in water.
Elemental Analysis; Calculated for C32H64N204.2-
H20, C49.71; H8.80, N3.62%, found C49.31; H8.39;
N3.16%
' The structural formula of the cis-bis-neodecanoato-
bis-cyclohexylamine-platinum (II)is as follows:
[CeH1; NH2.2—Pt—[OOC—C—R’'RR"}2
where R, R’, R” can be CH3, C2Hs or C3H7 to give a
carboxylato radical functions C1oH1902 (MW= 171) as
empirical formula.
EXAMPLE16
Preparation of
cis-bis-neodecanoatoethylenediamine-platinum (II)
H20.
Cis-diiodo-ethylenediamine-platinum (II), was first
prepared by the method of Example I, using ethylenedi-
amine ligand in place of ammonia and with a 96% yield
of product.
Sulfato-ethylenediamine-platinum (II). H2O waspre-
pared by the following method.
Cis-bis-diiodo-ethylenediamine-platinum (ID, (3.9)
was suspended in 10 ml H2O and an aqueoussolutions
of Ag2SOx4 (2.2 g in 200 ml H20) was added thereto.
The reaction mixture wasstirred in the dark overnight
at room temperature. AgI was removedbyfiltration
and the yellow filtrate was evaporated to dryness at
40°-45° C. under reduced pressure using rotary evapo-
ration. The final product was dried over P2O5 under
vacuum. The product yield was 2.35 g (81%).
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The compoundaccording to the invention was then
prepared as follows:
Sulfato-ethylenediamine-platinum (11), H2O (0.369 g)
was dissolved in H2O (20 ml) and a solution of sodium
neodecanoato prepared in situ (neodecanoic acid, 0.344
g in 20 mi methanol and IN NaOH, 2 ml) was added
thereto. The reaction mixture was stirred for 2-3 hr.at
room temperature. The reaction mixture was evapo-
rated to dryness at 40°-45° C. under reduced pressure
using rotary evaporation. A gummy product was ob-
tained which was extracted in chloroform and the chlo-
roform extract was dried over anhydrous MgSO4. The
MgSOgwas separated by filtration and the filtrate was
evaporated to dryness under reduced pressure using a
rotary evaporator. The final product was dried over
P2Os in vacuo. The product was stored at 0° C.
Elemental analysis; calculated for C22H4N2O04Pt.
H20, C42.86; H7.79; N 4.54%, found C43.07; H 7.32; N
4.71%.
Cis-bis-neodecanoato-ethylenediamine-platinum (IT)
is highly soluble in chloroform, methanol and other
organic solvents, but insoluble in water.
Thestructural formula of the cis-bis-neodecanoatoe-
thylenediamine-platinum (ID) is as foliows:
CH)—NH)
PtlOOC—C—R'R"};
CH2~—NH2
where R, R’, R" can be CH3, C2Hs or C3H7 to give a
carboxylato radical function CigH1902 (MW=171) as
empirical formula.
EXAMPLE17
Preparation of
cis-bis-neodecanoato-bis-isopropylamine-platinum (II)
Cis-bis-neodecanoato-bis-isopropylamine-platinum
(II) and sulfato-bis-isopropylamineplatinum (II) were
first prepared by the method of Example 16, using iso-
propylamine ligand in place of ethylenediamine.
The compound according to the invention was then
prepared as follows:
Sulfato-bis-isopropylamine-platinum (II). H2O (0.427
g) was dissolved in H2O (50 ml) and a solution ofsodi-
um-neodecanoato prepared in situ (neodecanoic acid
0.344 g in 20 ml of methanol and 1N NaOH,2 ml) was
added thereto. The reaction mixture was stirred for 2-3
hr. at room temperature. The reaction mixture was
evaporated to dryness at 40°-45° C. under reduced
pressure using rotary evaporator. A gummy mass was
obtained which was extracted in chloroform and the
chloroform extract was dried over anhydrous MgSOu.
The MgSO, was separated byfiltration and filtrate was
evaporated to dryness under reduced pressure using a
rotary evaporator. The product was dried over P2Os5 in
vacuo. Thefinal product was stored at 0° C.
Elemental analysis, calculated for CogHseN2O4Pt,
C47.63; H8.53; N4.26%; found C 47.74; H8.47; N
3.93%.
The structural formula of the cis-bis-neodecanoato-
bis-isopropylamine-platinum (II) is as follows:
({H3C}p,CH—NH3)2—Pt—[OOC—C_—R'RR"}2
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where R, R’, R” can be CH3, C2Hs or C3H7 to give a
carboxylato radical function with CjoH)902
(MW= 171) as an empirical formula.
Cis-bis-neodecanoato-bis-isopropylamine-platinum
(ID, is highly soluble in chloroform, methanol and other
organic solvents, but insoluble in water.
EXAMPLE18
Preparation of
cis-bis-decanoato-trans-R,R-1,2-diaminocyclohexane-
platinum I.
Sulfato-trans-R,R-1,2-diaminocyclohexane-platinum
TI H20 (0.423 g) was dissolved in HO (20 ml) and a
solution of sodium-decanoato preparedin situ (0.344 g
decanoic acid in. 20 ml methanol and IN NaOH 2 ml)
was added thereto. The reaction mixture was stirred for
2-3 hr. at room temperature. The reaction mixture was
evaporated to dryness at 40°-45° C. under reduced
pressure using a rotary evaporator. A solid was ob-
tained which was extracted in chloroform and chloro-
form extract was dried over anhydrous MgSO4. The
MgSOgwas removedbyfiltration andfiltrate was evap-
orated to dryness under reduced pressure using rotary
evaporator. The product was dried over P2Os in vacuo.
The final product was stored at 0° C.
Elemental analysis—calculated for C26Hs52N204Pt.-
H20 C46.59; H8.06; N 4.18%, found C 45.94; H7.87 N
4.31%. .
Cis-bis-decanoato _trans-R,R-1,2-diaminocyclohex-
ane-platinum II is highly soluble in chloroform and
other organic solvents, but insoluble in water.
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extract was evaporated to dryness and a cream-color
product was obtained. The product was dried over
P205 under vacuum.
Elemental analysis calculated for Cig6H32N2O04Pt.2-
H20; C35.00; H6.57; N5.11%, found C35.16; H6.17;
N5.27%.
Cis-bis-Neopentanoato-trans-R,R-1,2-diaminocy-
clohexane-platinum II, is highly soluble in chloroform,
methanol and other commonorganic solvents.
The structural formula of the cis-bis-neopentanoato-'
trans-R,R-1,2-diaminocyclohexane-platinum II is as
follows:
NH?
POCO(CHshz
NH?
EXAMPLE20
Encapsulation efficiency and antitumor activity of
lipophilic cisplatin analogs
The compounds prepared in Examples 14-19 were
tested for their efficiency of encapulation in liposomes
by the methods described in Example 6. These lipo-
some-encapsulated compounds were tested to deter-
mine their optimal dose and effectiveness as inhibitors
of in vivo tumor growth as described in Example 12.
The data in Table 12 reveal the resultant measurements.
TABLE12
Encapsulation Efficiency and Antitumor Activity of
Lipophilic Cisplatin Analogues Incorporated in Liposomes Optimal % T/C
 
Encapsulation dose 11210 ip/ip
Compound Efficiency mg/kg _single dose
Cis-bis-neodecanoato-cis-diamine-platinum (II) 95% 50 200
Cis-bis-neodecanoato-bis-cyclohexylamine-platinum (II) 89% 100 125
Cis-bis-neodecanoato-ethylenediamine-platinum (II) 82% 75 144
Cis-bis-neodecanoato-bis-isopropylamine-platinum (II) 87% 100 150
Cis-bis-decanoato-trans-R,R-1,2-diaminocyclohexane-platinum (IT) 96% 50 187
Cis-bis-neopentanoato-trans-R,R-1,2-diaminocyclohexane-platinum (IT) 93% 25 170
The structural formula of the cis-bis-decanoatotrans-
R,R-1,2-diaminocyclohexane-platinum II is as follows: 45
NH)
Pt(OOC(CH2)gCH3]2/ 50NH2 EXAMPLE21
In Vitro cytotoxicity against human malignantcell linesEXAMPLE19 tro ey ¥ against &
Cis-bi t RR Cis-bis-neodecanoato-1,2-diaminocyclohexane _plati-
1S-Dis-neopentanoato-trans-R,K-1, 55 num (II) was tested in the liposomal-form against three2-diaminocyclohexane-platinum IT.
Sulfato-trans-R,R-1,2-diaminocyclohexane-platinum
II. H20 (0.423 g) was dissolved in water (20 ml) and a
solution of barium-neopentanoato preparedin situ (neo-
pentanoic acid, 0.204 g, in 5 ml of methanol and Ba
(OH)2.8H20 0.3 g in 50 ml H2O combined together) was
added thereto. The reaction mixture wasstirred for 2-3
hr. at room temperature. The reaction mixture was
evaporated to dryness at 40°-45° C. under reduced
pressure using a rotary evaporator. The residue was
extracted with methanol, filtered and the filtrate was
evaporated to dryness. A solid was obtained which was
further extracted with chloroform. The chloroform
65
human malignantcell lines of colon carcinoma (LoVo,
SW620, and SW403) using a colony formation inhibi-
tion assay. The drug concentration that resulted in a
50% inhibition of colony formation (IC50) ranged from
4 to 8 uM. The IC50 of cisplatinum for these samecell
lines ranged from 3 to 7 uM.
Changes may be made in the various compositions,
elements, steps and procedures described herein with-
out departure from the concept and scopeof the inven-
tion as defined in the following claims.
Whatis claimedis:
1. A liposome comprising a phospholipid and a plati-
num (II) four-coordinate complex having the formula:
jointly 1,2-diaminocyclohexane.
- R,R-1,2-diaminocyclohexane
jointly alkyl-1,2-diamino having 2 to 12 carbon atoms.
5,186,94023 24
R’
R3 R} |/ —00C—C—RPr (Il)
“ZN 5 R"R2
wherein R; and Rzare each alkyl carboxylato bearing
a hydrophobic radical function or, when linked
together, are a dicarboxylato bearing a hydropho-
bic radical function, and wherein R3 and Rg are
each amines of the formula:
15
H|THRs
H 20
wherein Rsis selected from the group consisting of
hydrogen,alkyl, ary], aralky}, alkenyl, cycloalky],
or cycloalkenyl having between 1 and 20 carbon 25
atoms; or
wherein R3. and Ry, when linked together, are se-
lected from the group consisting of cycloalkyl-1,2-
diamino having between about 3 and 7 carbon 30
atoms, and alkyl-vicinal-diamino having between
. about 2 and 12 carbon atoms; and
said complex is defined further as being substantially
soluble in methanol or chloroform and substan- 3°
tially insoluble in water.
2. The liposome of claim 1, where R3 and Rg are
403. The liposomeof claim 2, where the 1,2-diaminocy-
clohexaneis in the R,R conformation.
4. The liposomeof claim 2, where the 1,2-diaminocy-
clohexaneis selected from the group consisting of trans- 45
and trans-S,S-1,2-
diaminocyclohexane.
5. The liposome of claim 1, where R3 and Ry are
50
6. The liposome of claim 1, where R; and R2 are
neodecanoato ofthe formula
55°
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where R, R’, and R”are selected from the group con-
sisting of —-CH3, --C2Hs, or —C3H7 to give a carbox-
ylato radical function C19H902 as an empirical for-
mula.
7. The liposome of claim 1, where Ri and R2 are
alkylcarboxylato having between about 5 and 20 carbon
atoms.
8. The liposome of claim 7, where R; and R2 are
branched chain alkylcarboxylato.
9. The liposome of claim 8, where Ri and R2 are
branched chain alkylcarboxylato having n carbon
atoms, and having the formula:
where two of R, R’ and R”are each methyl, ethyl, or
propyl, and the sum of the carbon atomsof R, R’, and
R”is n—2.
10. The liposome of claim 9, where n is 10.
11. The liposome of claim 9, where n is 5 and R, R’,
and R”are each methyl.
12. The liposomeof claim 1, 2, or 6, where the lipo-
some comprises at least one phospholipid selected from
the group consisting of phosphatidy! glycerol, phospha-
tidy] choline, sphingomyelin, phosphatidic acid, and
phosphatidy] serine.
13. The liposome of claim 12, further comprising
cholesterol. ° .
14. The liposome of claim 12, where the phospholipid
consists essentially of a mixture of phosphatidyl choline
and phosphatidyl glycerol.
15. The liposome of claim 14, where the molarratio
of phosphatidyl choline to phosphatidyl glycerol is
between about 1:10 and 10:1.
16. The liposomeof claim 12, where the phospholipid
consists essentially of a mixture of dimyristoyl phospha-
tidyl choline and dimyristoy] phosphatidyl glycerol.
17. The liposome of claim 16, where the molarratio
of dimyristoyl phosphatidyl choline to dimyristoyl
phosphatidyl glycerol is approximately 3:7.
18. The liposomeof claim 1, 2, or 6, where the ratio
of the platinum complex to the phospholipid is between
about 1:10 and about 1:30.
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